Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Prescribing information supports positioning of XACIATO as a first line option for the treatment of bacterial vaginosisThis marks the first FDA-approved product in Daré’s portfolio of potential first...
-
Significant progress on several key clinical and corporate initiatives with the portfolio during the third quarter, including DARE-BV1 NDA acceptance and Ovaprene NIH CRADA for the pivotal Phase 3 ...
-
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
-
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
-
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced its participation in DTC Perspectives’ Xpectives.Health...
-
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced a Notice of Award of a grant from the Eunice Kennedy Shriver...
-
Investigational therapy for women who cannot, or should not, take supplemental estrogen Potential to be the first treatment for vulvar and vaginal atrophy specifically developed for patients with...
-
SAN DIEGO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
-
SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
-
The discussion, Women’s Health Case Study: Optimizing Study Enrollment During the COVID-19 Pandemic, will review the DARE-BVFREE Phase 3 study that was successfully initiated and completed during 2020...